Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination

Bernard J. Cohen; Susette Audet; Nicholas Andrews; Judy Beeler

doi:10.1016/j.vaccine.2007.10.046

Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination

Bernard J. Cohen^*, Susette Audet, Nicholas Andrews, Judy Beeler

^*Corresponding author for this work

Pillar Testing Staff budget centre

Research output: Contribution to journal › Article › peer-review

160 Citations (Scopus)

Abstract

Background: Clinical trials of measles vaccination administered as aerosol are planned with the aim of obtaining licensure. Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy. Methods: A working group examined laboratory protocols for measles PRNT in use at three reference centres and agreed to a standardised procedure, which was subsequently validated. Results: Assay validation showed quantitative results varied approximately threefold both within and between assays. The lower limit of detection was approximately 20 milliInternational Units/mL. Conclusions: A standardised laboratory protocol for measles PRNT was established and validated for use in clinical trials of aerosolized measles vaccines.

Original language	English
Pages (from-to)	59-66
Number of pages	8
Journal	Vaccine
Volume	26
Issue number	1
DOIs	https://doi.org/10.1016/j.vaccine.2007.10.046
Publication status	Published - 21 Dec 2007

Bibliographical note

Funding Information:
WHO initiative for Vaccine Research co-ordinates the Measles Aerosol Project (MAP). The Centers for Disease Control and Prevention, USA and the American Red Cross are partners in MAP, which has received financial support from the Bill and Melinda Gates Foundation.

Keywords

Measles
Plaque reduction neutralization test

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2007.10.046

Cite this

@article{57234ab4a2af4454bbc34e7187fd1133,

title = "Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination",

abstract = "Background: Clinical trials of measles vaccination administered as aerosol are planned with the aim of obtaining licensure. Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy. Methods: A working group examined laboratory protocols for measles PRNT in use at three reference centres and agreed to a standardised procedure, which was subsequently validated. Results: Assay validation showed quantitative results varied approximately threefold both within and between assays. The lower limit of detection was approximately 20 milliInternational Units/mL. Conclusions: A standardised laboratory protocol for measles PRNT was established and validated for use in clinical trials of aerosolized measles vaccines.",

keywords = "Measles, Plaque reduction neutralization test",

author = "Cohen, {Bernard J.} and Susette Audet and Nicholas Andrews and Judy Beeler",

note = "Funding Information: WHO initiative for Vaccine Research co-ordinates the Measles Aerosol Project (MAP). The Centers for Disease Control and Prevention, USA and the American Red Cross are partners in MAP, which has received financial support from the Bill and Melinda Gates Foundation. ",

year = "2007",

month = dec,

day = "21",

doi = "10.1016/j.vaccine.2007.10.046",

language = "English",

volume = "26",

pages = "59--66",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - Plaque reduction neutralization test for measles antibodies

T2 - Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination

AU - Cohen, Bernard J.

AU - Audet, Susette

AU - Andrews, Nicholas

AU - Beeler, Judy

N1 - Funding Information: WHO initiative for Vaccine Research co-ordinates the Measles Aerosol Project (MAP). The Centers for Disease Control and Prevention, USA and the American Red Cross are partners in MAP, which has received financial support from the Bill and Melinda Gates Foundation.

PY - 2007/12/21

Y1 - 2007/12/21

N2 - Background: Clinical trials of measles vaccination administered as aerosol are planned with the aim of obtaining licensure. Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy. Methods: A working group examined laboratory protocols for measles PRNT in use at three reference centres and agreed to a standardised procedure, which was subsequently validated. Results: Assay validation showed quantitative results varied approximately threefold both within and between assays. The lower limit of detection was approximately 20 milliInternational Units/mL. Conclusions: A standardised laboratory protocol for measles PRNT was established and validated for use in clinical trials of aerosolized measles vaccines.

AB - Background: Clinical trials of measles vaccination administered as aerosol are planned with the aim of obtaining licensure. Measles antibody levels will be measured using the plaque reduction neutralization test (PRNT) to assess antibody responses as a surrogate marker of efficacy. Methods: A working group examined laboratory protocols for measles PRNT in use at three reference centres and agreed to a standardised procedure, which was subsequently validated. Results: Assay validation showed quantitative results varied approximately threefold both within and between assays. The lower limit of detection was approximately 20 milliInternational Units/mL. Conclusions: A standardised laboratory protocol for measles PRNT was established and validated for use in clinical trials of aerosolized measles vaccines.

KW - Measles

KW - Plaque reduction neutralization test

UR - http://www.scopus.com/inward/record.url?scp=36749043225&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.10.046

DO - 10.1016/j.vaccine.2007.10.046

M3 - Article

C2 - 18063236

AN - SCOPUS:36749043225

SN - 0264-410X

VL - 26

SP - 59

EP - 66

JO - Vaccine

JF - Vaccine

IS - 1

ER -

Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this